Company intelligence / Profile preview

DIFMETRE

Ascoli Piceno, Italy

Ownership: Private
Development stage: Other

Overview

FB Health is an Italian pharmaceutical company specializing in the development and commercialization of products for the prevention and treatment of diseases in the psychiatric and neurological fields. The company is widely recognized for its flagship product, Difmetre, a combination therapy used for the acute treatment of migraine attacks. FB Health focuses on addressing unmet needs in Central Nervous System (CNS) disorders through a portfolio of both pharmaceutical drugs and nutraceuticals. In 2017, the company was acquired by Neuraxpharm, a leading European specialty pharmaceutical company focused on CNS, which has since integrated FB Health's operations to expand its footprint in the Italian market.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on DIFMETRE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIFMETRE.

Explore the full profile